BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 1356875)

  • 1. Mechanism of ebrotidine protection against gastric mucosal injury induced by ethanol.
    Slomiany BL; Piotrowski J; Murty VL; Slomiany A
    Gen Pharmacol; 1992 Jul; 23(4):719-27. PubMed ID: 1356875
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ebrotidine--a new H2-receptor antagonist with mucosal strengthening activity.
    Piotrowski J; Yamaki K; Morita M; Slomiany A; Slomiany BL
    Biochem Int; 1992 Mar; 26(4):659-67. PubMed ID: 1351724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protection against alcohol-induced gastric mucosal injury by nitecapone.
    Slomiany BL; Piotrowski J; Ismail A; Rajiyah G; Tamura S; Bielanski W; Slomiany A
    Gen Pharmacol; 1991; 22(6):1055-62. PubMed ID: 1810804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gastroprotective properties of ebrotidine. A review.
    Slomiany BL; Piotrowski J; Slomiany A
    Arzneimittelforschung; 1997 Apr; 47(4A):459-67. PubMed ID: 9205744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of ebrotidine on ethanol-induced gastric mucosal damage in the rat. Comparative study with other H2-receptor antagonists.
    Palop D; Romero A; Villamayor F; Conejo L; Sacristán A; Ortiz JA
    Arzneimittelforschung; 1997 Apr; 47(4A):450-4. PubMed ID: 9205742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of tumor necrosis factor-alpha and apoptosis in gastric mucosal injury by indomethacin: effect of omeprazole and ebrotidine.
    Slomiany BL; Piotrowski J; Slomiany A
    Scand J Gastroenterol; 1997 Jul; 32(7):638-42. PubMed ID: 9246701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhancement in the protective qualities of gastric mucus by ebrotidine during duodenal ulcer healing.
    Slomiany BL; Piotrowski J; Majka J; Czajkowski A; Slomiany A; Gabryelewicz A
    Gen Pharmacol; 1995 Sep; 26(5):1039-44. PubMed ID: 7557247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancement of gastric mucus phospholipid secretion by an antiulcer agent, ebrotidine.
    Slomiany BL; Piotrowski E; Piotrowski J; Zirvi KA; Liau YH; Murty VL; Slomiany A
    Gen Pharmacol; 1994 Sep; 25(5):1033-7. PubMed ID: 7835621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gastroprotective and ulcer-healing activities of a new H2-receptor antagonist: ebrotidine.
    Brzozowski T; Majka J; Konturek SJ
    Digestion; 1992; 51(1):27-36. PubMed ID: 1353465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Studies on the cytoprotective and antisecretory activity of ebrotidine. A review.
    Konturek PC; Brzozowski T; Konturek SI; Márquez M; Torres J; Ortiz JA
    Arzneimittelforschung; 1997 Apr; 47(4A):578-89. PubMed ID: 9205769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of ebrotidine on gastric mucosal calcium channel activity.
    Slomiany BL; Liu J; Kawai T; Czajkowski A; Slomiany A
    Am J Gastroenterol; 1993 Jun; 88(6):881-6. PubMed ID: 8099251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Study on the increment of the amount of gastric mucus in rats after repeated-dose administration of ebrotidine.
    Romero A; Villamayor F; Palop D; Falcó J; Sacristán A; Ortiz JA
    Arzneimittelforschung; 1997 Apr; 47(4A):455-8. PubMed ID: 9205743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of gastric mucosal calcium channel activity by an antiulcer agent, ebrotidine.
    Slomiany BL; Liu J; Piotrowski J; Czajkowski A; Yotsumoto F; Slomiany A
    J Physiol Pharmacol; 1994 Mar; 45(1):121-31. PubMed ID: 7519082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancement in the protective qualities of gastric mucus with combination therapy of ebrotidine and amoxicillin for H. pylori eradication.
    Slomiany BL; Piotrowski J; Slomiany A; Konturek JW; Domschke WW
    Gen Pharmacol; 1998 Aug; 31(2):227-31. PubMed ID: 9688464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Involvement of endogenous nitric oxide and sulfhydryl compounds in ebrotidine-induced gastroprotection.
    Palop D; Conejo L; Sacristán A; Ortiz JA
    Arzneimittelforschung; 1997 Apr; 47(4A):468-71. PubMed ID: 9205745
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Studies on the protective effect of ebrotidine on experimental ulcers induced by non-steroidal anti-inflammatory drugs in healthy volunteers.
    Puscas I; Puscas C; Coltau M; Torres J; Márquez M; Herrero E; Fillat O; Ortiz JA
    Arzneimittelforschung; 1997 Apr; 47(4A):565-8. PubMed ID: 9205766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histamine H2-receptor antagonist action of ebrotidine. Effects on gastric acid secretion, gastrin levels and NSAID-induced gastrotoxicity in the rat.
    Palop D; Agut J; Márquez M; Conejo L; Sacristán A; Ortiz JA
    Arzneimittelforschung; 1997 Apr; 47(4A):439-46. PubMed ID: 9205740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-Helicobacter pylori activities of ebrotidine. A review of biochemical and animal experimental studies and data.
    Slomiany BL; Piotrowski J; Slomiany A
    Arzneimittelforschung; 1997 Apr; 47(4A):475-82. PubMed ID: 9205747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gastric mucosal apoptosis induced by ethanol: effect of antiulcer agents.
    Piotrowski J; Piotrowski E; Skrodzka D; Slomiany A; Slomiany BL
    Biochem Mol Biol Int; 1997 Jun; 42(2):247-54. PubMed ID: 9238522
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention and healing of experimental indomethacin-induced gastric lesions: effects of ebrotidine, omeprazole and ranitidine.
    Arroyo MT; Lanas A; Sáinz R
    Eur J Gastroenterol Hepatol; 2000 Mar; 12(3):313-8. PubMed ID: 10750652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.